1 1 = 3. combined use of anti-her2 agents in the neoadjuvant setting
Published 5 months ago • 4 plays • Length 9:30Download video MP4
Download video MP3
Similar videos
-
6:06
combining anti-her2 agents with immunotherapy for her2 mbc
-
0:55
neoadjuvant treatment approach for her2 positive breast cancer
-
4:04
neoadjuvant t-dm1 in her2 early breast cancer
-
22:50
neoadjuvant therapy for her2-positive breast cancer - dr. scott christensen
-
1:42
her2dx and pcr in her2-positive breast cancer: a combined analysis of 4 neoadjuvant studies
-
13:29
asco guideline: her2 testing in breast cancer
-
22:59
asco 2013 - breast cancer (neo-adjuvant therapy in her2 )
-
17:40
case 3: potential role of neoadjuvant therapy in a 61 yo woman with t2 n3 her2 /er-/pr- bc
-
1:37
dr. bhave on promising anti-her2 agents in her2 breast cancer
-
8:47
chemotherapy and targeted therapy for her2-negative metastatic breast cancer that is either endoc...
-
1:39
dr. hurvitz on the lack of predictive biomarkers in her2 breast cancer
-
2:49
her2-e pcr with anti-her2-based neoadjuvant therapies
-
9:36
biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer guideline update
-
16:19
case 1: potential role of neoadjuvant therapy for a 30 yo woman with t2 n1 bc
-
13:34
systemic therapy for advanced her2-positive breast cancer guideline update
-
3:20
dr. hurvitz on eliminating anthracyclines in her2 breast cancer treatment
-
8:13
systemic therapy for patients with advanced her2 positive breast cancer guideline
-
0:56
dr. jhaveri discusses the utility of t-dm1 in the neoadjuvant setting
-
8:31
#esmo21 expert video report on her2-positive early breast cancer